Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Development of a Novel Composite Process Measure for Venous Thromboembolism Prophylaxis.

Kinnier CV, Ju MH, Kmiecik T, Barnard C, Halverson T, Yang AD, Caprini J, Kreutzer L, Bilimoria KY.

Med Care. 2016 Feb;54(2):210-7. doi: 10.1097/MLR.0000000000000474.

PMID:
26683781
2.

Risk of discharge to postacute care: a patient-centered outcome for the american college of surgeons national surgical quality improvement program surgical risk calculator.

Mohanty S, Liu Y, Paruch JL, Kmiecik TE, Cohen ME, Ko CY, Bilimoria KY.

JAMA Surg. 2015 May;150(5):480-4. doi: 10.1001/jamasurg.2014.3176.

PMID:
25806660
3.

Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer.

Merkow RP, Bentrem DJ, Mulcahy MF, Chung JW, Abbott DE, Kmiecik TE, Stewart AK, Winchester DP, Ko CY, Bilimoria KY.

Ann Surg. 2013 Dec;258(6):847-53. doi: 10.1097/SLA.0000000000000312.

PMID:
24169157
4.

Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons.

Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmiecik TE, Ko CY, Cohen ME.

J Am Coll Surg. 2013 Nov;217(5):833-42.e1-3. doi: 10.1016/j.jamcollsurg.2013.07.385. Epub 2013 Sep 18.

5.

Hormonal determinants of nipple aspirate fluid yield among breast cancer cases and screening controls.

Fought AJ, McGathey C, Scholtens DM, Heinz RE, Lowe R, Feeney YB, Lee O, Kmiecik TE, Wolfman JA, Clevenger CV, Gann PH, Gapstur S, Chatterton RT, Khan SA.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2277-84. doi: 10.1158/1055-9965.EPI-12-0434. Epub 2013 Sep 18.

6.

Effect of including cancer-specific variables on models examining short-term outcomes.

Merkow RP, Kmiecik TE, Bentrem DJ, Winchester DP, Stewart AK, Ko CY, Bilimoria KY.

Cancer. 2013 Apr 1;119(7):1412-9. doi: 10.1002/cncr.27891. Epub 2012 Nov 26.

7.

T lymphocytes as a target of histamine action.

Kmiecik T, Otocka-Kmiecik A, Górska-Ciebiada M, Ciebiada M.

Arch Med Sci. 2012 Feb 29;8(1):154-61. doi: 10.5114/aoms.2012.27295.

8.

Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis.

Ciebiada M, Gorska-Ciebiada M, Barylski M, Kmiecik T, Gorski P.

Am J Rhinol Allergy. 2011 Jan-Feb;25(1):e1-6. doi: 10.2500/ajra.2011.25.3540.

PMID:
21711959
9.

Personalized medicine gets practical.

Sanders D, Kmiecik T.

Healthc Inform. 2009 May;26(5):50-1. No abstract available.

PMID:
19514241
10.

Development of an online morbidity, mortality, and near-miss reporting system to identify patterns of adverse events in surgical patients.

Bilimoria KY, Kmiecik TE, DaRosa DA, Halverson A, Eskandari MK, Bell RH Jr, Soper NJ, Wayne JD.

Arch Surg. 2009 Apr;144(4):305-11; discussion 311. doi: 10.1001/archsurg.2009.5.

PMID:
19380642
11.

Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine.

Ciebiada M, Ciebiada MG, Kmiecik T, DuBuske LM, Gorski P.

J Investig Allergol Clin Immunol. 2008;18(5):343-9.

12.

Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine.

Kmiecik T, Arnoux S, Kobryn A, Gorski P.

J Asthma. 2007 Dec;44(10):817-22.

PMID:
18097856
13.

[Safety of influenza vaccination in asthmatics].

Kmiecik T, Sek K, Górski P.

Pneumonol Alergol Pol. 2006;74(4):365-71. Polish.

PMID:
17427144
14.

Gene transfer of multidrug resistance into a factor-dependent human hematopoietic progenitor cell line: in vivo model for genetically transferred chemoprotection.

Schwarzenberger P, Spence S, Lohrey N, Kmiecik T, Longo DL, Murphy WJ, Ruscetti FW, Keller JR.

Blood. 1996 Apr 1;87(7):2723-31.

15.

Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells.

Kmiecik TE, Keller JR, Rosen E, Vande Woude GF.

Blood. 1992 Nov 15;80(10):2454-7.

16.

Evidence for non-covalent clusters of the c-met proto-oncogene product.

Faletto DL, Tsarfaty I, Kmiecik TE, Gonzatti M, Suzuki T, Vande Woude GF.

Oncogene. 1992 Jun;7(6):1149-57.

PMID:
1317541
17.

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.

Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA.

Science. 1991 Feb 15;251(4995):802-4.

PMID:
1846706
18.

Altered tyrosine 527 phosphorylation and mitotic activation of p60c-src.

Bagrodia S, Chackalaparampil I, Kmiecik TE, Shalloway D.

Nature. 1991 Jan 10;349(6305):172-5.

PMID:
1702522
19.

Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene.

Iyer A, Kmiecik TE, Park M, Daar I, Blair D, Dunn KJ, Sutrave P, Ihle JN, Bodescot M, Vande Woude GF.

Cell Growth Differ. 1990 Feb;1(2):87-95.

20.

Regulation by the autophosphorylation site in overexpressed pp60c-src.

Kmiecik TE, Johnson PJ, Shalloway D.

Mol Cell Biol. 1988 Oct;8(10):4541-6.

21.
22.

The cellular src gene product regulates junctional cell-to-cell communication.

Azarnia R, Reddy S, Kmiecik TE, Shalloway D, Loewenstein WR.

Science. 1988 Jan 22;239(4838):398-401.

PMID:
2447651

Supplemental Content

Loading ...
Support Center